Traders Buy High Volume of uniQure N.V. Call Options (QURE)

uniQure N.V. (NASDAQ:QURE) saw unusually large options trading activity on Wednesday. Stock investors acquired 3,043 call options on the stock. This is an increase of 806% compared to the typical volume of 336 call options.

QURE has been the subject of several research reports. Zacks Investment Research cut shares of uniQure N.V. from a “buy” rating to a “hold” rating in a research note on Thursday, August 24th. Leerink Swann raised their target price on shares of uniQure N.V. from $19.00 to $26.00 in a research note on Tuesday, November 7th. Evercore ISI initiated coverage on shares of uniQure N.V. in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, ValuEngine cut shares of uniQure N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. uniQure N.V. has an average rating of “Buy” and an average target price of $17.43.

uniQure N.V. (NASDAQ:QURE) opened at $15.81 on Friday. uniQure N.V. has a 52 week low of $4.72 and a 52 week high of $21.35. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.

Several large investors have recently added to or reduced their stakes in QURE. FMR LLC grew its stake in shares of uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after buying an additional 122,700 shares in the last quarter. Morgan Stanley grew its stake in shares of uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock valued at $3,271,000 after buying an additional 73,418 shares in the last quarter. Mangrove Partners grew its stake in shares of uniQure N.V. by 167.4% in the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 66,763 shares in the last quarter. Finally, OxFORD Asset Management LLP bought a new position in shares of uniQure N.V. in the third quarter valued at $399,000. 25.07% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Traders Buy High Volume of uniQure N.V. Call Options (QURE)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/25/traders-buy-high-volume-of-uniqure-n-v-call-options-qure.html.

About uniQure N.V.

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

What are top analysts saying about uniQure N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for uniQure N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit